Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide

被引：246

作者：

Schade, Sebastian ^{[1
]}

Mollenhauer, Brit ^{[2
,3
]}

Trenkwalder, Claudia ^{[2
,4
]}

机构：

[1] Univ Med Ctr Gottingen, Dept Clin Neurophysiol, Robert Koch Str 40, D-37075 Gottingen, Germany

[2] Paracelsus Elena Klin, Klin Str 16, D-34128 Kassel, Germany

[3] Univ Med Ctr Gottingen, Dept Neurol, Gottingen, Germany

[4] Univ Med Ctr Gottingen, Dept Neurosurg, Gottingen, Germany

来源：

MOVEMENT DISORDERS CLINICAL PRACTICE | 2020年 / 7卷 / 03期

关键词：

levodopa equivalent dose; LED; opicapone; safinamide;

D O I：

10.1002/mdc3.12921

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：343 / 345

页数：3

共 5 条

[1]

Espay AJ, 2017, NEUROL-CLIN PRACT, V7, P86, DOI 10.1212/CPJ.0000000000000316

[2] Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions [J].

Ferreira, J. J. ;

Lees, A. ;

Rocha, J. -F. ;

Poewe, W. ;

Rascol, O. ;

Soares-da-Silva, P. .

EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (07) :953-960

[3] Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review [J].

Katsaiti, Irene ;

Nixon, John .

JOURNAL OF PARKINSONS DISEASE, 2018, 8 (02) :217-231

[4] Safinamide: an add-on treatment for managing Parkinson's disease [J].

Mueller, Thomas .

CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2018, 10 :31-41

[5] Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease [J].

Tomlinson, Claire L. ;

Stowe, Rebecca ;

Patel, Smitaa ;

Rick, Caroline ;

Gray, Richard ;

Clarke, Carl E. .

MOVEMENT DISORDERS, 2010, 25 (15) :2649-2653

← 1 →